{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:34:13Z","timestamp":1794278053689,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eclinm.2024.102576","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:18:05Z","timestamp":1712380685000},"page":"102576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial"],"prefix":"10.1016","volume":"71","author":[{"given":"Paolo","family":"Mulatero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Wuerzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Groessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sconfienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Damianaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Forestiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gerlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eclinm.2024.102576_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102576_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102576_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J\u00a0Hypertens"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102576_bib4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/HJH.0000000000002520","article-title":"Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102576_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102576_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn's registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102576_bib7","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A\u00a0double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102576_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2024.102576_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.644260","article-title":"Composite cardiovascular outcomes in patients with primary aldosteronism undergoing medical versus surgical treatment: a meta-analysis","volume":"12","author":"Huang","year":"2021","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102576_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J\u00a0Intern Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102576_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102576_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102576_bib13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"18","key":"10.1016\/j.eclinm.2024.102576_bib14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2024.102576_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"Menard","year":"2014","journal-title":"J\u00a0Transl Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102576_bib16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1751-7176.2012.00667.x","article-title":"The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study","volume":"14","author":"Andersen","year":"2012","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102576_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102576_bib18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102576_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"},{"issue":"10424","key":"10.1016\/j.eclinm.2024.102576_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102576_bib21","article-title":"LY3045697: results from two randomized clinical trials of a novel inhibitor of aldosterone synthase","volume":"18","author":"Sloan-Lancaster","year":"2017","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102576_bib22","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/bcp.15713","article-title":"CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers","volume":"89","author":"Mulatero","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102576_bib23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1210\/jcem-52-2-214","article-title":"Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients","volume":"52","author":"Gomez-Sanchez","year":"1981","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102576_bib24","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.eclinm.2024.102576_bib25","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.160.16.2429","article-title":"New guidelines for potassium replacement in clinical practice: a contemporary review by the national council on potassium in clinical practice","volume":"160","author":"Cohn","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102576_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.eclinm.2024.102576_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106409","article-title":"Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate","volume":"235","author":"Pignatti","year":"2023","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102576_bib28","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.resuscitation.2010.08.015","volume":"81","author":"Soar","year":"2010","journal-title":"Resuscitation"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102576_bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102576_bib30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/ME.2014-1410","article-title":"Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury","volume":"29","author":"Ashton","year":"2015","journal-title":"Mol Endocrinol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102576_bib31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102576_bib32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/HYPERTENSIONAHA.118.11382","article-title":"Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism","volume":"72","author":"Williams","year":"2018","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102576_bib33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial","volume":"4","author":"Dekkers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102576_bib34","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10008","key":"10.1016\/j.eclinm.2024.102576_bib35","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102576_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702400155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702400155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:51:17Z","timestamp":1760737877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702400155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"alternative-id":["S258953702400155X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102576","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102576"}}